Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of CMV-Specific T-Lymphocytes in Post-Transplant Patients
NCT04018261Phase 2Completed
- Sponsor
- Banc de Sang i Teixits
- Start
- Jul 2019
- Primary completion
- Oct 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in cytomegalovirus infection (CMV), sponsored by Banc de Sang i Teixits. Primary endpoint: Adverse Events at 60 days. Started Jul 2019; status: completed.
02
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT04018261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04018261.